Consortium Meeting of the project 3DLIVER: “Innovative Human-Derived 3D Liver Models for Drug Toxicity Testing and Discovery”.

Leitat Technological Center together with industry partner Readycell and public research institution Vall d’Hebron Institut de Recerca (VHIR) recently celebrated their 1-year Consortium Meeting of the project 3DLIVER: “Innovative Human-Derived 3D Liver Models for Drug Toxicity Testing and Discovery”.

The main aim of the 3DLIVER project is the generation of innovative human liver-derived 3D in vitro models as innovative ready-to-use kits for drug testing models, using human liver cells and extracellular matrix (ECM), to generate more reliable in vitro drug testing devices.

The project consortium involves leading partners in different expertise areas to ensure the success of this innovative proposal. Members of the Donation and Transplant Coordination Department as well as both the Paediatric Hepatic Transplants Unit and the Hepatobiliary and Pancreatic Surgery and Transplants Department from Vall d’Hebron University Hospital, and their respective research groups (Donation and transplantation of organs, tissues and cells and transplantation and HBPI and Liver Transplantation) from Vall d’Hebron Institut de Recerca (VHIR), the Medical Department from Leitat Technological Center and Industry partner ReadyCell S.L., have shared the advances in their activities in 3DLIVER.

A huge thanks to all the consortium members participating for the great discussion contributing to a very fruitful meeting.

The 3DLIVER project was awarded the competitive grant “Proyectos en Colaboración Público-Privada2021” from the Spanish Ministry of Science and Innovation (Ministerio de Ciencia e Innovación) through its funding agency Agencia Estatal de Investigación (AEI).
Project CPP2021-008633 funded by MCIN/AEI/10.13039/501100011033 y por la Unión Europea “NextGenerationEU”/PRTR: